Are you a Trader or Investor: Biotech Momentum Is Picking Up…Update-1
Update-1 11/22…Another good day but as the S&P 500 approaches 4,600 we are near the top of the range from Aug 1, when the recent sell-off began. The QQQ hit a new high at 390 exceeding the JUL 19 high of 385. Small cap biotechs that we track continue to have...Another Weak Month for Healthcare and Biotech Stocks: What’s going on?,,,,Update-2….Small cap rally!
Update-2 Small cap biotech rally continues..11/15/23.. 10:30am EST……As per previous post we are now in the beginning of an SMID Rally.See our post from last week with potential trades many of which are already up 10% or more:ABOS, CRBU, CRSP, CYRX, PACB,...Healthcare Playbook: Hardly Defensive with a Covid Hangover in Biotech…Update-2…smallcaps moving!
Update-2 11/4/23…Small caps starting to show momentum after a big week with QQQ up over 6%, IWM up 7.56%, IJR up 7.45%. Seasonality of Q4 gains off to a good start. Broad market rally was sparked by lower bond yields. Even MRNA launches off bottom after...Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield etc. Update-2… After a challenging week
Update-2 10/30…10:30a EDT Rally or not? I will post tomorrow to see if rally holds from gloomy sentiment driven by MACRO. Stocks we follow that are up on opening: ABBV, LLY, MRK. SMID biotech and MEDTECH stocks are still not tradeable: DHR an TMO are red...Raygent Healthcare Portfolio Focus Stocks…Update-1…ABT, MRK
Update-2 10/20 Merck (MRK) pops over 2% to $102+ on ADC deal with Daiichi Sankyo. Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the...Large Cap Biopharmaceuticals-Core Holdings for Your Healthcare Portfolio Until M&A Action Picks UP…Update-4…JNJ
Update-4 10/17…JNJ now reporting as a stand-alone biopharmaceutical and medical device Company raised its profit forecast helped by demand from it anti-inflammatory drug Stelara and reported a gain of $21 B from the spin-off of its consumer health unit Kenvue....Three of our Top Picks for Your Healthcare Portfolio…Update-4…ABBV, GEHC,UNH….
Update-4 10/7…We will update our biopharma playbook next week with a focus on large caps. Our current picks are: Abbvie (ABBV), Lilly (LLY), Regeneron (REGN), and Vertex (VRTX); Pfizer (PFE) is a contrarian trade for value and good news. Update-3 10/6…A...Healthcare Portfolio: A Mixed Market Looking for Value…Update-2
9/8/23…215 EDT B.of A. upgrades laggard Gilead Sciences (GILD) stock rises 2.5% to $75 handle. Div. 3.96%,FWD PE 10.45, P/S 3.44. 9/8/23…10:45 EDT.Markets follow 10 yr yield with rally at 4.22%. As yield rises markets weaker. S&P at 4468 up 0.38%. As...Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results but Lilly is a Big Winner…Update-2
Best stock picks in large cap biopharma.